NewAmsterdam Pharma Warrant (NAMSW)

• Market cap: $98.5M
• 5 days: 8.41%
• 1 month: -10.61%
• 3 months: -16.24%
• 6 months: 100.84%
• Year to date: -7.32%
• 1 year: 113.25%
• 5 years: 2,332.95%
• 10 years: 2,332.95%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77